Clinical Trials Browser

Carcinoma, Non-Small-Cell Lung

NCT06477055 2026-04-13

RAISE

Phase 2 Recruiting

60 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT06741085 2026-04-13

A Study of Stereotactic Radiosurgery (SRS) and Standard Treatment in People With Lung Cancer That Has Spread to the Brain

Phase 2 Recruiting

56 enrolled

Thoracic

Non Small Cell Lung Cancer Metastatic

NCT07295821 2026-04-08

NSCLC

Phase 2 Recruiting

60 enrolled

Thoracic

Lung Neoplasms

NCT03586453 2026-04-03

Osimertinib In EGFR Mutant Lung Cancer

Phase 2 Recruiting

30 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT07505173 2026-04-01

HOPE-WBRT

Phase 2 Recruiting

74 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT07379476 2026-02-12

Local Ablative Therapy to Oligoresidual Metastasis in EGFR Mutated Non-small Cell Lung Cancer

Phase 2 Recruiting

64 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT07375316 2026-02-10

A ctDNA-guided Phase II Trial of Osimertinib in Combination With Sacituzumab Tirumotecan in EGFR-mutated Advanced NSCLC Patients With Positvie ctDNA After lead-in Osimertinib Monotherapy

Phase 2 Recruiting

120 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT05642572 2025-12-05

Comparing Combinations of Targeted Drugs for Advanced Non-Small Cell Lung Cancer That Has EGFR and MET Gene Changes (A Lung-MAP Treatment Trial)

Phase 2 Recruiting

66 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT07229729 2025-12-01

A Study of SHR-A2102 in Combination With Other Anti-tumor Therapies for Resectable Non-small Cell Lung Cancer

Phase 2 Recruiting

300 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT07058519 2025-11-26

A Study of Osimertinib-based Adaptive Treatment Guided by ctDNA EGFRm+ Monitoring in NSCLC

Phase 2 Recruiting

250 enrolled

Thoracic

Locally Advanced or Metastatic EGFRm Non-small Cell Lung Cancer (NSCLC)

NCT04410796 2025-11-06

Osimertinib Alone or With Chemotherapy for EGFR-Mutant Lung Cancers

Phase 2 Recruiting

571 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT04591002 2025-06-26

Osimertinib to Suppress the Progression of GGN(EGFR Mutation-positive)

Phase 2 Recruiting

43 enrolled

Thoracic

Lung Neoplasms

NCT06574347 2025-05-21

KYLIN-2

Phase 2 Recruiting

120 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT06498986 2025-05-07

A Study of BL-B01D1 in Combination With Osimertinib Mesylate Tablets in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer

Phase 2 Recruiting

40 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT06014827 2025-05-04

Biologically Guided Radiation Therapy (BgRT) and Stereotactic Body Radiation Therapy (SBRT) to Tyrosine Kinase Inhibitor in Oligoprogressive Oncogenic Positive Non-Small Cell Lung Carcinoma

Phase 2 Recruiting

32 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT06895928 2025-04-22

A Trial of SHR-A2102 With Other Antitumor Therapies in Advanced Solid Tumors

Phase 2 Recruiting

400 enrolled

Other solid neoplasm

Advanced Solid Tumors

NCT05281406 2025-02-21

Additional Chemotherapy for EGFRm Patients with the Continued Presence of Plasma CtDNA EGFRm At Week 3 After Start of Osimertinib 1st-line Treatment (PACE-LUNG)

Phase 2 Recruiting

50 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT05948813 2024-11-21

TY-9591 in the Patients With EGFR Mutations in Advanced NSCLC With Brain Metastases

Phase 2 Recruiting

420 enrolled

CNS

Brain Neoplasms

NCT04322890 2024-10-22

PIKACHU

Phase 2 Recruiting

6,000 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT06383728 2024-05-09

GALAXY-02

Phase 2 Recruiting

51 enrolled

Thoracic

Carcinoma, Squamous Cell, Lung Neoplasms

NCT05528458 2024-04-23

Osimertinib to Suppress the Progression of Remaining GGN for EGFR Mutation-positive Stage IB-IIIA Lung Adenocarcinoma

Phase 2 Recruiting

59 enrolled

Thoracic

Adenocarcinoma of Lung

NCT06363734 2024-04-16

Osimertinib Plus Dalpiciclib in Patients With EGFR-mutant, CDK4/6 Pathway Aberrant, Advanced Non-small Cell Lung Cancer Following Acquired Resistance to Third-generation EGFR TKI: a Phase II Trial

Phase 2 Recruiting

32 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT05011487 2024-01-16

NOCE01

Phase 2 Recruiting

30 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT05686434 2023-01-17

Osimertinib Therapy After Resection in High-risk Stage I EGFRm NSCLC (OSTAR)

Phase 2 Recruiting

65 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung

Clinical Trials

Testing Osimertinib as a Treatment for Lung Cancers With an EGFR Exon 20 Change

RAISE

A Study of Stereotactic Radiosurgery (SRS) and Standard Treatment in People With Lung Cancer That Has Spread to the Brain

NSCLC

Osimertinib In EGFR Mutant Lung Cancer

HOPE-WBRT

Local Ablative Therapy to Oligoresidual Metastasis in EGFR Mutated Non-small Cell Lung Cancer

A ctDNA-guided Phase II Trial of Osimertinib in Combination With Sacituzumab Tirumotecan in EGFR-mutated Advanced NSCLC Patients With Positvie ctDNA After lead-in Osimertinib Monotherapy

Comparing Combinations of Targeted Drugs for Advanced Non-Small Cell Lung Cancer That Has EGFR and MET Gene Changes (A Lung-MAP Treatment Trial)

A Study of SHR-A2102 in Combination With Other Anti-tumor Therapies for Resectable Non-small Cell Lung Cancer

A Study of Osimertinib-based Adaptive Treatment Guided by ctDNA EGFRm+ Monitoring in NSCLC

Osimertinib Alone or With Chemotherapy for EGFR-Mutant Lung Cancers

Osimertinib to Suppress the Progression of GGN(EGFR Mutation-positive)

KYLIN-2

A Study of BL-B01D1 in Combination With Osimertinib Mesylate Tablets in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer

Biologically Guided Radiation Therapy (BgRT) and Stereotactic Body Radiation Therapy (SBRT) to Tyrosine Kinase Inhibitor in Oligoprogressive Oncogenic Positive Non-Small Cell Lung Carcinoma

A Trial of SHR-A2102 With Other Antitumor Therapies in Advanced Solid Tumors

Additional Chemotherapy for EGFRm Patients with the Continued Presence of Plasma CtDNA EGFRm At Week 3 After Start of Osimertinib 1st-line Treatment (PACE-LUNG)

TY-9591 in the Patients With EGFR Mutations in Advanced NSCLC With Brain Metastases

PIKACHU

GALAXY-02

Osimertinib to Suppress the Progression of Remaining GGN for EGFR Mutation-positive Stage IB-IIIA Lung Adenocarcinoma

Osimertinib Plus Dalpiciclib in Patients With EGFR-mutant, CDK4/6 Pathway Aberrant, Advanced Non-small Cell Lung Cancer Following Acquired Resistance to Third-generation EGFR TKI: a Phase II Trial

NOCE01

Osimertinib Therapy After Resection in High-risk Stage I EGFRm NSCLC (OSTAR)